Akademik Veri Yönetim Sistemi
UNION OF THRACE UNIVERSITIES V. INTERNATIONAL HEALTH SCIENCES CONGRESS 2022, Balıkesir, Türkiye, 1 - 02 Aralık 2022, ss.295
In the literature, new therapeutic applications that can be an alternative to the routine pharmacological agent treatment used in the clinic in ulcerative colitis (UC) continue to be investigated. One of these alternative applications is probiotic supplementation (PS). Probiotics are microorganisms that can have positive effects on various metabolic reactions when consumed in a certain amount. Probiotic bacteria isolated from foods or living tissues can be applied to the organism as a single strain or as a mixture of different strains to provide metabolic benefits. Among the main metabolic contributions of PS to the treatment of UC; There is the presence of short-chain fatty acids (SCFA), which are released because of the alteration of the intestinal microbiota pattern of dysbiotic character and the fermentation of prebiotics. Butyrate, one of the aforementioned SCFA components, protects colon health; it contributes by using it as a substrate by colonocytes. It has also been shown that butyrate increases mucin secretion in intestinal epithelial cells and regulates intestinal permeability by strengthening the structure of tight junction proteins in these cells. With the application of probiotics, an increase is observed in the density and amount of genera such as “Lactobacillus” and “Bifidobacterium”, which are beneficial bacteria in the intestinal microbiota pattern; in this way, the amount of pathogenic bacteria in the microflora composition can be reduced. In addition, beneficial bacteria reduce the expression of proinflammatory cytokines and play a role in suppressing inflammation by increasing the expression of anti-inflammatory cytokines. Despite the positive metabolic effects of PS on UC, the metabolic effects of strains or products may vary. Therefore, more detailed studies are needed to elucidate all aspects of the potential of PS as an alternative therapeutic agent in the treatment of UC.